321 related articles for article (PubMed ID: 31392046)
1. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
Weinberg BA; Xiu J; Lindberg MR; Shields AF; Hwang JJ; Poorman K; Salem ME; Pishvaian MJ; Holcombe RF; Marshall JL; Morse MA
J Gastrointest Oncol; 2019 Aug; 10(4):652-662. PubMed ID: 31392046
[TBL] [Abstract][Full Text] [Related]
2. Current biologics for treatment of biliary tract cancers.
Zhao DY; Lim KH
J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
4. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
5. KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
7. Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.
Mitiushkina NV; Tiurin VI; Anuskina AA; Bordovskaya NA; Shestakova AD; Martianov AS; Bubnov MG; Shishkina AS; Semina MV; Romanko AA; Kuligina ES; Imyanitov EN
Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37891989
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
[TBL] [Abstract][Full Text] [Related]
12. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Mody K; Starr J; Saul M; Poorman K; Weinberg BA; Salem ME; VanderWalde A; Shields AF
J Gastrointest Oncol; 2019 Dec; 10(6):1099-1109. PubMed ID: 31949927
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.
Jacobi O; Ross JS; Goshen-Lago T; Haddad R; Moore A; Sulkes A; Brenner B; Ben-Aharon I
Oncol Res Treat; 2021; 44(1-2):20-27. PubMed ID: 33279901
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract][Full Text] [Related]
15. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
Queiroz MM; Lima NF; Biachi de Castria T
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
[TBL] [Abstract][Full Text] [Related]
17. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
Sasaki M; Nitta T; Sato Y; Nakanuma Y
Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
[TBL] [Abstract][Full Text] [Related]
19. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
20. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
